Journal of Gynecologic Oncology

Papers
(The TQCC of Journal of Gynecologic Oncology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Nomogram for predicting pathology upstaging in patients with EIN: is sentinel lymph node assessment useful in these patients?217
Increased cardiovascular disease risk among adolescent and young adult survivors of cervical cancer53
Laparoscopic radical hysterectomy without uterine manipulator or vaginal tube use46
Developing standardized informed consent for hysterectomy and vulva cancer surgery39
Para-aortic lymph node dissection with or without nerve-sparing in gynecological malignancies31
Impact of adjuvant chemotherapy on the overall survival of patients with resectable bulky small cell neuroendocrine cervical cancer: a JSGO-JSOG joint study28
One more opportunity in early-stage cervical cancer: the role of photodynamic therapy in managing positive surgical margins23
Development of an homologous recombination deficiency scoring algorithm for unmatched ovarian tumor sample based on next-generation sequencing22
Circ_0075960 targets the miR-202-5p/CTNND1 axis to promote the growth and migration of endometrial carcinoma cells via regulating Wnt/β-catenin signaling activity22
Practice guideline for management of endometrial cancer in Thailand: a Thai Gynecologic Cancer Society consensus statement21
The efficacy of the levonorgestrel intrauterine system versus oral megestrol acetate in treating atypical endometrial hyperplasia: a superior randomized controlled trial21
Comparison of clinical outcomes between early and delayed diagnosis of cervical cancer following abnormal Pap smear results: a population-based cohort study using National Health Insurance data in Sou19
Evaluation of secondary cytoreduction surgery in platinum-resistant ovarian cancer patients within three-line recurrent: a multicenter, randomized controlled study19
Missing a chance to prevent: disparities in completion of genetic evaluation in high-risk patients with endometrial cancer18
Optimal number of neoadjuvant chemotherapy cycles prior to interval debulking surgery in advanced epithelial ovarian cancer: a systematic review and meta-analysis of progression-free survival and over18
Neoadjuvant therapy of iparomlimab and tuvonralimab combined with chemotherapy-extenuated for locally advanced cervical cancer (NICE-CC): an investigator-initiated, multicentre, open-label, phase II t18
Comparison of the effect of oral megestrol acetate with or without levonorgestrel-intrauterine system on fertility-preserving treatment in patients with early-stage endometrial cancer: a prospective, 17
Clinical practice guideline for high-risk human papillomavirus testing in cervical cancer screening: a consensus statement from the Korean Society of Gynecologic Oncology17
Diagnostic accuracy of the droplet digital PCR POLE mutation test in endometrial cancer: comparison with Sanger sequencing and NGS17
Intensified radiochemotherapy with cisplatin and gemcitabine for cervical cancer in the modern era: a retrospective cohort study17
Impact of the diagnosis-surgery interval on survival outcomes and development of a nomogram for predicting survival in early-stage cervical cancer: a Surveillance, Epidemiology, and End Results databa17
Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey17
Current peritonectomy practice during debulking surgery in patients with newly diagnosed advanced ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 4004)17
Is restaging surgery quintessential in suspected early-stage epithelial ovarian cancer? An ancillary study of the Gynecologic Oncology Research Investigators coLLaborAtion study (GORILLA-3002)17
Pregnancy complications and outcomes in patients with early endometrial cancer or atypical hyperplasia after fertility-sparing treatment17
Evaluation of the role of liver metastasectomy in the treatment of stage IV endometrial cancer16
Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review16
Elucidation of genomic origin of synchronous endometrial and ovarian cancer (SEO) by genomic and microsatellite analysis16
Fertility-sparing treatment outcomes using immune checkpoint inhibitors in endometrial cancer patients with Lynch syndrome15
Adjuvant treatment algorithm based on recent ESGO/ESTRO/ESP guidelines for early endometrial carcinoma according to prognostic risk groups15
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses15
Functions, interactions and prognostic role of POLE: a bioinformatics analysis14
LKB1 attenuates the transport activity of GLUT1 by regulating the alternative splicing of PKM1/PKM2 in cervical cancer14
Salvage hysterectomy for persistent residual cervical cancer: assessment of prognostic factors14
Enhanced ovarian cancer diagnosis using deep learning on pelvic ultrasound with integrated clinical data: retrospective multicenter study14
Efficacy and toxicity of PARP inhibitor in elderly patients with homologous recombination-deficient newly diagnosed advanced ovarian cancer: the role of dose modification13
Supragastric lesser sac: an insidious site for surgical exploration during the debulking surgery in advanced ovarian cancer13
RAD51/geminin/γH2AX immunohistochemical expression predicts platinum-based chemotherapy response in ovarian high-grade serous carcinoma13
Efficacy and safety of immune checkpoint inhibitors with chemoradiotherapy/chemotherapy in locally advanced cervical cancer patients: a systematic review and single-arm meta-analysis13
Diagnostic accuracy and prognostic factors of uterine serous carcinoma in Japanese women: a multi-center study13
Genotype distribution and risk factors for human papillomavirus infection13
Noninvasive early warning markers for ovarian cancer: a Mendelian randomization study12
Prognostic significance of psoas muscle index at diagnosis in cervical cancer progression12
Prognostic significance of heterologous component in carcinosarcoma of the gynecologic organs: a systematic review and meta-analysis12
Diagnostic performance of cervical cytology in HPV-independent cervical cancer: a comparative analysis with HPV-associated cases12
Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer12
Risk of CIN2+ in women aged >60 years with abnormal cervical cancer screening: a multicenter retrospective cohort study from the Thai Gynecologic Cancer Society research group12
East Asian Gynecologic Oncology Trial Group (EAGOT): founding history and future perspective12
Therapeutic effects of surgical debulking of metastatic lymph nodes in cervical cancer IIICr: a trial protocol for a phase III, multicenter, randomized controlled study (KGOG1047/DEBULK trial)12
Enrichment for the POLE mutated against p53 wild subtype using clinicopathologic factors and cyclin B1 immunohistochemistry in endometrial cancer12
Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis11
Cervical screening among Chinese females in the era of HPV vaccination: a population-based survey on screening uptake and regular screening following an 18-year organized screening program11
Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis11
A multimodal intervention program to improve sexual health and self-perceived quality of life in patients treated for cervical cancer: a randomized prospective study (PROVIDENCE trial)11
Fertility and prognosis assessment between bleomycin/etoposide/cisplatin and paclitaxel/carboplatin chemotherapy regimens in the conservative treatment of malignant ovarian germ cell tumors: a multice11
Preoperative serum microRNAs as potential prognostic biomarkers in ovarian clear cell carcinoma10
Comparison of oncologic outcome of preoveratively presumed low-risk endometrial cancer patients who underwent only bilateral pelvic sentinel lymph node (SLN) removal and those who underwent pelvic lym10
Cost-effectiveness of atezolizumab plus chemotherapy for advanced/recurrent endometrial cancer10
HER2-negative or low expression as an unfavorable prognostic factor in patients with stage I/II uterine carcinosarcoma10
Humanized patient-derived xenograft mouse model bearing ovarian clear cell carcinoma10
Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy10
Postoperative radiation therapy in women with FIGO stage I clear cell and papillary serous carcinomas of the uterus: an analysis of the SEER database10
Development and validation of a prognostic model based on metabolic risk score to predict overall survival of endometrial cancer in Chinese patients10
Cost-effectiveness analysis of hospital treatment volume and survival outcomes in endometrial cancer in Japan9
Clinical implications of the superficial uterine vein pattern for the dissection of the anterior layer of the vesicouterine ligament in radical hysterectomy9
Differentiation of uterine fibroids and sarcomas by MRI and serum LDH levels: a multicenter study of the KAMOGAWA study9
Validation of molecular classification on diagnostic biopsy in endometrial carcinoma: the first step for a tailored approach9
Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a “real-life setting”9
Adjuvant carboplatin and paclitaxel with “sandwich” method radiotherapy for stage III or IV endometrial cancer: long-term follow-up at a single-institution9
Identification of the prognostic immune subtype in copy-number high endometrial cancer9
Adjuvant pelvic radiation versus observation in intermediate-risk early-stage cervical cancer patients following primary radical surgery: a propensity score-adjusted analysis9
The necessity of adjuvant surgery for patients with high-risk chemorefractory or relapsed gestational choriocarcinoma with complete remission after anti-PD-1 therapy9
Navigating the future of fertility preservation: advanced predictive strategies for treatment outcomes of endometrial atypical hyperplasia and carcinoma9
Implementation rate and related factors of confirmatory tests following an abnormal Pap smear: a nationwide study from the National Health Insurance9
Intra- and postoperative complications associated with diaphragmatic surgery for advanced ovarian cancer9
Laparoscopy-assisted laterally extended endopelvic resection and sacrectomy (beyond laterally extended endopelvic resection) for platinum-sensitive recurrent ovarian cancer9
The sealing effect of magnetic-sealing uterine manipulator in isolated uterus from patients with early-stage cervical cancer: a pre-clinical study8
Alternative splicing of PSMD13 mediated by genetic variants is significantly associated with endometrial cancer risk8
Update of incidence and survival in patients with cervical cancer in the United States from 2000 to 20218
LncRNA linc01194 promotes the progress of endometrial carcinoma by up-regulating SOX2 through binding to IGF2BP18
A phase II trial evaluating the efficacy and safety of repeated high dose medroxyprogesterone acetate (MPA) therapy for patients with recurrent early-stage endometrial cancer or atypical endometrial h8
RAIDS atlas of significant genetic and protein biomarkers in cervical cancer8
Reviewer recognition in 20248
Chemotherapy plus camrelizumab for fertility preservation (NACI-F) in FIGO stage IB1 cervical cancer: a multicenter, single-arm, phase 2 trial8
Bevacizumab combined with chemotherapy could be superior to chemotherapy alone in relapsed ovarian cancer after PARPi: evidence from a multi-center propensity score-matched analysis8
Risk of ovarian cancer in women with pelvic inflammatory disease and homologous recombination repair gene mutations under 55: a population-based cohort study7
The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma7
Th2 cells infiltrating high-grade serous ovarian cancer: a feature that may account for the poor prognosis7
Asian Society of Gynecologic Oncology (ASGO) 2024 Annual Meeting in Bali, Indonesia7
Clinical application value of the updated FIGO 2023 classification compared with FIGO 2009 for endometrial cancer staging in a Chinese cohort7
Erratum: The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women’s cancer research organization7
Validation of HPV triage in cytology-based cervical cancer screening for ASC-US cases using Japanese data7
Response to Corcept’s retraction request on manuscript of “Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study”7
Evolving standards and future directions for systemic therapies in cervical cancer7
Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia7
Evaluation of clinical usefulness of HPV-16 and HPV-18 genotyping for cervical cancer screening7
Comparison of progression-free survival outcome of sentinel node biopsy without ultrastaging versus lymphadenectomy in endometrial cancer: a propensity-matched analysis7
Can surgery boost the survival benefit of chemoradiotherapy in T1b1-T2a1 stage cervical cancer with lymph node metastasis? A population-based study7
The SHAPE trial: is good is good enough?6
Subsequent primary cancer incidence in cervical cancer survivors: insights from a comprehensive cohort study utilizing combined Japanese population-based cancer registries6
The 8th Biennial Meeting of the Asian Society of Gynecologic Oncology, December 1st to 3rd, 20236
PARP inhibitor maintenance takes advantages in advanced epithelial ovarian cancer but May show a negative impact while recurrence occurs: a multi-center retrospective study in Taiwan6
Revisiting the meaning of Trousseau sign and syndrome6
CircSMAD2 accelerates endometrial cancer cell proliferation and metastasis by regulating the miR-1277-5p/MFGE8 axis6
Treatment patterns and prognosis of vulvar cancer: a nationwide retrospective analysis from the JSOG tumor registry (2016–2020)6
Cancer-field surgery for endometrial cancer by robotic peritoneal mesometrial resection and targeted compartmental lymphadenectomy (PMMR+TCL)6
Effect of adjuvant treatment on survival in 2023 FIGO stage IIC endometrial cancer6
Comparison of carboplatin-based chemotherapy versus cisplatin-based chemotherapy in the treatment of malignant gonadal germ cell tumor: a systematic review and meta-analysis6
Incidence and treatment outcomes of uterine cervical cancer in Korea 1999–2018 from the national cancer registry6
Improved bladder function in radical hysterectomy without worsening oncologic outcome: resection of the posterior layer of the vesicouterine ligament with the procedure limited to the vesical veins6
Minimally invasive radical hysterectomy and the importance of avoiding cancer cell spillage for early-stage cervical cancer: a narrative review6
Platinum free interval and clinical benefit of the second-line chemotherapy in recurrent uterine and ovarian carcinosarcoma: a retrospective cohort analysis6
Sentinel node mapping in endometrial cancer6
Clinical practice guidelines for cervical cancer: an update of the Korean Society of Gynecologic Oncology Guidelines6
Gram-positive targeting antibiotics are associated with progression and death in women with platinum-sensitive recurrent high grade epithelial ovarian cancer6
Bispecific immunotherapy MEDI5752 or volrustomig and cervical cancer6
Timing of adjuvant radiotherapy for early-stage endometrial carcinoma: a single-center retrospective cohort study6
The pathologic and clinical outcomes of risk-reducing salpingo-oophorectomy in asymptomatic carriers of homologous recombination repair gene mutation6
Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer5
Cost-effectiveness of pembrolizumab plus chemotherapy for advanced endometrial cancer5
Challenges and perspectives on less invasive surgery for early-stage cervical cancer: a critical analysis of the SHAPE trial and its implications5
Targeting BRAF pathway in low-grade serous ovarian cancer5
Comparison of mRNA-based and next-generation sequencing HPV assays in a population-based cervical cancer screening program in China5
Efficacy and prognosis of robotic surgery with sentinel node navigation surgery in endometrial cancer5
An overview of the current debate between using minimally invasive surgery versus laparotomy for interval cytoreductive surgery in epithelial ovarian cancer5
Interleukin-34 cancels anti-tumor immunity by PARP inhibitor5
Intraoperative frozen pathology exam of Common iliac lymph nodes and Para-Aortic lymphadenectomy on the prognosis and quality of life for patients with IB2-IIA2 Cervical Cancer: trial protocol for a r5
Abnormal p53 expression is associated with poor outcomes in grade I or II, stage I, endometrioid carcinoma: a retrospective single-institute study5
Trends and characteristics of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer in Japan: a survey by the Gynecologic Oncology Committee of the Japan Society of O5
Long-term chemotherapy-induced peripheral neuropathy evaluated using patient-reported outcomes in gynecologic malignancies5
Prevention of symptomatic pulmonary embolism for gynecologic malignancies with preoperative asymptomatic venous thromboembolism: GOTIC-VTE trial5
Agreement between INDICAID™ HPV (human papillomavirus) Urine Test and BD Onclarity™ HPV Assay in detection of high-risk HPV in self-collected urine samples5
Comprehensive assessment of incidence, mortality, and lifetime risk of ovarian cancer: a global study with forecasts to 20505
Poor accuracy of endometrial sampling in patients with uterine carcinosarcomas: a nationwide analysis5
p16(INK4a) immunohistochemical expression is a strong predictor of treatment response and survival in patients with locally advanced squamous cell vulvar cancer undergoing upfront chemoradiotherapy5
PTEN mutation predicts unfavorable fertility preserving treatment outcome in the young patients with endometrioid endometrial cancer and atypical hyperplasia5
Current treatment strategies for ovarian cancer in the East Asian Gynecologic Oncology Trial Group (EAGOT)5
Postoperative conventional versus hypofractionated intensity-modulated radiation therapy with concurrent chemotherapy in cervical cancer: a prospective multicenter randomized phase III trial (POHIM_P35
Prevalence and prognostic value of PD-L1 expression and tumor mutational burden in persistent, recurrent, or metastatic cervical cancer5
Mutations in homologous recombination repair genes in patients with metastatic endometrial cancer: association with clinical characteristics and prognosis5
Prognostic values of tumor size and location in early stage endometrial cancer patients who received radiotherapy5
Missing a chance to prevent: disparities in completion of genetic evaluation in high-risk patients with endometrial cancer5
Diagnostic significance and predictive efficiency of metabolic risk score for fertility-sparing treatment in patients with atypical endometrial hyperplasia and early endometrial carcinoma5
External validation of the SUCCOR Risk score for predicting recurrence in early-stage cervical cancer patients treated with radical hysterectomy5
Erratum: Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer5
Prognostic factors and optimal management approaches for stage IB uterine leiomyosarcoma: a retrospective analysis5
Radical hysterectomy or chemoradiotherapy for clinically early-stage cervical cancer with suspicious lymph nodes on imaging: a retrospective cohort study5
0.12409710884094